Anavex Life Sciences Corp. (AVXL)

5.70
NASDAQ
Prev Close 5.54
Day Low/High 5.55 / 5.74
52 Wk Low/High 2.43 / 8.30
Exchange NASDAQ
Shares Outstanding 41.38B
Market Cap 229.22M
Div & Yield N.A. (N.A)

Latest News

Tech Does the Heavy Lifting

Is the market setting up for a painful reversal?

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.

Quarter Starts on Wrong Foot

Bank funds, retail stocks suffer reversals.

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

First Week Of AVXL May 19th Options Trading

Investors in Anavex Life Sciences Corp saw new options become available this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVXL options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

Interesting AVXL Put And Call Options For October 20th

Investors in Anavex Life Sciences Corp saw new options begin trading this week, for the October 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Noble Capital Markets Initiates Research Coverage On Anavex Life Sciences Corp. (AVXL)

Noble Capital Markets, a leading small-cap focused investment firm, announces the initiation of research coverage of Anavex Life Sciences.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

Interesting AVXL Put And Call Options For February 2017

Interesting AVXL Put And Call Options For February 2017

Investors in Anavex Life Sciences Corp saw new options begin trading this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVXL options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.

Biotechs Bolstered on 21st Century Cures Passage

Biotechs Bolstered on 21st Century Cures Passage

Biotechs were trading at high volumes Thursday morning on news that the Senate has passed the 21st Century Cures Act.

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Gold, Utilities, Bonds Post Gains

I stopped out of Lantheus Holdings for a small loss and bought Baozun near $15.